Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry
Launched by RUSH UNIVERSITY MEDICAL CENTER · Dec 4, 2023
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
The CNA-FWRD Registry is a clinical trial that is studying how well different treatments work for people who experience recurrent vasovagal syncope (a fainting spell often triggered by stress or pain) and slow heart rhythms (bradyarrhythmias). The trial aims to understand the effects of medical therapy, a specific heart procedure called radiofrequency catheter ablation (which helps to correct heart rhythm problems), and the use of a pacemaker (a device that helps control the heartbeat) in managing these conditions.
To be eligible for this study, participants need to be under 60 years old and have symptoms of vasovagal syncope or bradyarrhythmia that haven't improved with other treatments. Unfortunately, individuals over 60 or those with certain heart conditions cannot participate. If you join the study, you will be managed with routine care and may receive one of the treatments being studied. This trial is currently recruiting participants and hopes to gather important information to improve care for those with these heart-related issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • symptomatic vasovagal syncope or symptomatic bradyarrhythmia refractory to behavioral and medical measures
- • age \< 60 years
- Exclusion Criteria:
- • age \> 60 years
- • intra-/infra-Hisian AV block
- • intrinsic sinus node disease
- • history of supraventricular tachycardia
- • history of ventricular tachycardia
- • presence of structural heart disease related
- • prior history of catheter ablation
- • presence of inheritable arrhythmic conditions
- • orthostatic hypotension on HUTT test
- • abnormal thyroid function levels
- • Proven indication for permanent pacemaker implantation
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Tolga Aksu, MD
Study Chair
Yepedite University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported